Immune Checkpoint Inhibitors in the Treatment of Selected Tumor Types:
A New Direction

Saturday, April 23, 2016
7:00 AM - 4:15 PM

Program Director
Fredrick B. Hagemeister, MD
Professor of Hematology/Oncology,
Department of Lymphoma/Myeloma,
Division of Cancer Medicine,
University of Texas MD Anderson Cancer Center,
Houston, TX

Educational Grants
This activity is supported by education grants from:
Bristol-Myers Squibb & AstraZeneca

Jointly provided by

For online registration and more information visit: www.cancernetus.com

REGISTRATION FORM

First Name ___________________ Middle Initial _____ Last Name ________________
☐ Physician ☐ Pa-C ☐ NP ☐ PhD ☐ Pharmacist ☐ Industry ☐ Nurse ☐ Other
Mailing Address ____________________________________________

City ______________________ State ______ Zip Code ________________
Phone ___________________ Fax _________________________________
E-Mail _______________________________________________________

Speciality ___________________

Registration Fee (Registration fee partially covers buffet breakfast, lunch and syllabus book)

<table>
<thead>
<tr>
<th></th>
<th>Early Registration Fee - Up to 3/31/16</th>
<th>Discounted Registration Fee - 4/1/16 - 4/15/16</th>
<th>Regular Registration Fee - 4/16/16 - 4/23/16</th>
</tr>
</thead>
<tbody>
<tr>
<td>Physicians</td>
<td>$100.00</td>
<td>$130.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Nurses, Nurse Practitioners, Physician Assistants</td>
<td>$75.00</td>
<td>$85.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Pharmacists, Fellows</td>
<td>$75.00</td>
<td>$85.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Industry†</td>
<td>$300.00</td>
<td>$400.00</td>
<td>$450.00</td>
</tr>
</tbody>
</table>

† Person(s) employed by for-profit organizations such as pharmaceutical and biotech companies, and financial institutions

Fax registration to: 443-267-0016
Mail registration to:
860 Hebron Pkwy, Suite 1104
Lewisville, TX 75057
☐ Check box to receive information about Live and Webcast programs. You can unsubscribe at any time.

No refund. Substitution is allowed.

Payment may be made: ☐ MC ☐ Visa ☐ Discover ☐ Check
Credit Card Number ___________________________ Expiration Date __________

Name and address (as given on the monthly credit card statement) ________________________________

Pharmacists only: NABP e-profile # __________ Birth Date (MMDD): __________

Signature ________________

Register online at www.cancernetus.com
Please make checks payable to CancerNet. Mail checks to CancerNet, 860 Hebron Pkwy, Suite 1104, Lewisville, TX 75057
To reserve your place for the meeting, please complete the registration form and fax it to 443-267-0016. For questions, if any, please call Brian Waggoner at 972-459-5222 or E-mail: brianw@cancernetus.com
Immune Checkpoint Inhibitors in the Treatment of Selected Tumor Types: A New Direction
Saturday, April 23, 2016
Houston Marriott at the Texas Medical Center
6580 Fannin Street, Houston, TX 77030
Phone: 713-796-0080

Statement of Need / Program Overview
This symposium is intended to improve care of patients with immunotherapeutic options for selected tumor types by accelerating adoption of new evidence-based practice change. The format will include didactic lectures from known opinion leaders, question and answer sessions, and ample opportunity for participant interaction with faculty.

Target Audience
This symposium is directed primarily to hematologists/oncologists, researchers, pharmacists, registered nurses, physician assistants, nurse practitioners and fellows in training interested in new development in immunotherapy options for selected tumor types. No specific skill or knowledge other than a basic training in hematology/oncology is required for successful participation in this activity.

Learning Objectives
After completing this activity, the participant should be better able to:
• Explain the mechanisms of action of checkpoint inhibitors and their impact on novel therapies in cancer
• Identify current strategies in immunotherapy combination with molecular therapies in cancer
• Evaluate and implement immunotherapy options for malignant melanoma
• Identify current strategies in treatment of non-small-cell lung cancer utilizing immune checkpoint pathway inhibitors
• Identify currently accruing immunotherapy options for head & neck cancer
• Identify patterns of response with emerging immunotherapy options for hematological malignancies
• Describe the emerging immunotherapeutic approaches for renal cell carcinoma
• Describe emerging immunotherapeutic approaches for bladder cancer
• Identify currently accruing immunotherapy options for prostate cancer
• Select immunotherapy options for hepatic and gastrointestinal cancers
• Identify the role of neoantigens in the immunotherapy options for ovarian cancer
• Increase the awareness of currently accruing immunotherapy modality combination clinical trials across tumor types
• Differentiate the safety profile between conventional and immunotherapy treatment option for cancer
• Describe the role of prognostic and predictive biomarkers in the immunotherapeutic approaches
• Evaluate the unique toxicity issues with immunotherapy options across tumor types

Faculty
David Carbone, MD, PhD
Professor of Internal Medicine, Barbara J. Bonner Chair in Lung Research, Director of James Thoracic Center, The Ohio State University, Columbus, OH

Robert Coleman, MD
Professor, Department of Gynecologic Oncology and Reproductive Medicine, University of Texas MD Anderson Cancer Center, Houston, TX

Michael Davies, MD, PhD
Associate Professor, Department of Melanoma Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Don L. Gibbons, MD, PhD
Assistant Professor, Depts. of Thoracic, Head/Neck Medical Oncology & Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX

James L. Gulley, MD, PhD
Senior Investigator/Head, Immunotherapy Section, Director of the Medical Oncology Service, National Cancer Institute, Bethesda, MD

Fredrick B. Hagemeister, MD
Professor of Hematology/Oncology, Department of Lymphoma/ Myeloma, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX

John V. Heymach, MD, PhD
Professor and Chair, Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Eric Jonasch, MD
Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Michael Overman, MD
Associate Professor, GI Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX

Padmanee Sharma, MD, PhD
Professor, Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX

William N. William, Jr., MD
Associate Professor, Chief Head & Neck Section, Department of Thoracic/Head and Neck Medical Oncology, Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00 AM</td>
<td>Breakfast and Registrations</td>
<td>Frederick Hagemeister, MD</td>
</tr>
<tr>
<td>8:25 AM</td>
<td>Welcome and Introductions</td>
<td></td>
</tr>
<tr>
<td>8:30 AM</td>
<td>Checkpoint Inhibition: A Perspective into Future of Novel Therapies for Cancer</td>
<td>Don Gibbons, MD, PhD</td>
</tr>
<tr>
<td>9:00 AM</td>
<td>Immunotherapy Combination with Molecular Therapy</td>
<td>David Carbone, MD, PhD</td>
</tr>
<tr>
<td>9:30 AM</td>
<td>BREAK</td>
<td></td>
</tr>
<tr>
<td>9:45 AM</td>
<td>Malignant Melanoma</td>
<td>Michael Davies, MD</td>
</tr>
<tr>
<td>10:10 AM</td>
<td>Lung Cancer</td>
<td>John V. Heymach, MD, PhD</td>
</tr>
<tr>
<td>10:35 AM</td>
<td>Head &amp; Neck Cancers</td>
<td>William A. William, MD</td>
</tr>
<tr>
<td>11:00 AM</td>
<td>Hematological Malignancies</td>
<td>Fredrick B. Hagemeister, MD</td>
</tr>
<tr>
<td>11:25 AM</td>
<td>Renal Cell Carcinoma</td>
<td>Eric Jonasch, MD</td>
</tr>
<tr>
<td>11:50 AM</td>
<td>Bladder Cancer</td>
<td>Padmanee Sharma, MD, Ph</td>
</tr>
<tr>
<td>12:15 PM</td>
<td>Prostate Cancer</td>
<td>TBD</td>
</tr>
<tr>
<td>12:40 PM</td>
<td>LUNCH</td>
<td></td>
</tr>
<tr>
<td>1:40 PM</td>
<td>Hepatic and Gastrointestinal Cancer</td>
<td>Michael Overman, MD</td>
</tr>
<tr>
<td>2:05 PM</td>
<td>Ovarian Cancer - Neoantigens</td>
<td>Robert Coleman, MD</td>
</tr>
<tr>
<td>2:30 PM</td>
<td>Selecting Immunotherapy Modalities for Combination Therapies</td>
<td>James L. Gulley, MD, PhD</td>
</tr>
<tr>
<td>3:00 PM</td>
<td>BREAK</td>
<td></td>
</tr>
<tr>
<td>3:15 PM</td>
<td>Biomarkers for Cancer Immunotherapy</td>
<td>Don Gibbons, MD, PhD</td>
</tr>
<tr>
<td>3:45 PM</td>
<td>Management of Toxicity Issues with Immunotherapy</td>
<td>John V. Heymach, MD, PhD</td>
</tr>
<tr>
<td>4:15 PM</td>
<td>Closing Remarks and Adjourn</td>
<td>Frederick Hagemeister, MD</td>
</tr>
</tbody>
</table>

Credit Designation:
This activity provides 6.25 contact hours (0.625 CEUs) - Application based credits
ACPE Universal Activity Number: 0280-9999-16-001-L01-P

Participant Requirements (Nurses and Pharmacists) for Credit:
- Participants must fully attend all sessions as well as pass in a completed signature verification form (No partial credit will be given).
- Participants can earn Continuing Education credits for this program by electronically logging onto the website https://ce.ahrevents.com/ and completing the session evaluation form for sessions attended.
- Nurses: After completion of the evaluation, certificate of credit can be printed.
- Pharmacists: After completion of the activity evaluation, pharmacy education credit is automatically reported to CPE Monitor where a certificate of credit can be printed. Please allow up to 48 hours for credit to be available on the CPE Monitor.
- Only Certificates of Credit Issued from CPE Monitor are valid in the US
- CPE Monitor will not accept credits after 60 days from the session date
- All participant names will be checked against program attendance sheets for verification of attendance.

Disclosure & Evaluation:
All participants will have the opportunity to evaluate the educational session and presenter as well as the ability to identify their future educational needs. Disclosure will be made on the day of the program regarding any interest or affiliation a speaker may have with a supporting organization.

Participants may reserve guest rooms by calling (713) 796-0080